Keros Therapeutics logo
Keros Therapeutics
KROS | NASDAQ
Chart Builder DCF Calculator
$10.03
-$0.27 (-2.62%)
At close: Nov 16, 2026, 4:00 PM ET
$10.18
+$0.15 (+1.50%)
After-hours: Nov 16, 2026, 7:30 PM ET

Keros Therapeutics Company Profile

Company profile explained

Company Profile

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

Key Executives

Name Position
Jasbir S. Seehra President, Chief Executive Officer & Director
Esther Cho Chief Legal Officer & Secretary
Annita Tanini VP of Finance, Corporate Controller and Interim Principal Financial & Accounting Officer
Justin Frantz Head of Investor Relations
Lorena Lerner Chief Scientific Officer

Latest SEC Filings

Date Type Title
Oct 27, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Sep 29, 2026 8-K Current Report
Sep 28, 2026 8-K Current Report
Sep 16, 2026 EFFECT Filing
Sep 11, 2026 DEL AM Filing
Sep 10, 2026 S-3 Filing
Sep 08, 2026 8-K Current Report
Aug 20, 2026 4 Filing
Aug 20, 2026 4 Filing
Aug 20, 2026 4 Filing
View All SEC Filings ➞
Keros Therapeutics
Keros Therapeutics logo
Country United States
IPO Date Apr 8, 2020
Industry Biotechnology
Sector Healthcare
Employees 92
CEO Jasbir S. Seehra

Contact Details

1050 Waltham Street Lexington, Massachusetts 02421 United States

Stock Details

Ticker Symbol KROS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001664710
CUSIP Number 492327101
ISIN Number US4923271013
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.